Trevi Therapeutics Stock Alpha and Beta Analysis
| TRVI Stock | USD 2.88 0.04 1.37% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Trevi Therapeutics. It also helps investors analyze the systematic and unsystematic risks associated with investing in Trevi Therapeutics over a specified time horizon. Remember, high Trevi Therapeutics' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Trevi Therapeutics' market risk premium analysis include:
Beta 1.69 | Alpha (0.17) | Risk 3.99 | Sharpe Ratio 0.0154 | Expected Return 0.0614 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Trevi |
Trevi Therapeutics Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Trevi Therapeutics market risk premium is the additional return an investor will receive from holding Trevi Therapeutics long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Trevi Therapeutics. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Trevi Therapeutics' performance over market.| α | -0.17 | β | 1.69 |
Trevi Therapeutics expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Trevi Therapeutics' Buy-and-hold return. Our buy-and-hold chart shows how Trevi Therapeutics performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Trevi Therapeutics Market Price Analysis
Market price analysis indicators help investors to evaluate how Trevi Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Trevi Therapeutics shares will generate the highest return on investment. By understating and applying Trevi Therapeutics stock market price indicators, traders can identify Trevi Therapeutics position entry and exit signals to maximize returns.
Trevi Therapeutics Return and Market Media
The median price of Trevi Therapeutics for the period between Thu, Aug 29, 2024 and Wed, Nov 27, 2024 is 3.1 with a coefficient of variation of 5.78. The daily time series for the period is distributed with a sample standard deviation of 0.18, arithmetic mean of 3.09, and mean deviation of 0.14. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | Disposition of 3863 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3 | 09/03/2024 |
2 | Disposition of 4219 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3 | 09/06/2024 |
3 | Disposition of 1840 shares by Jennifer Good of Trevi Therapeutics at 1.43 subject to Rule 16b-3 | 09/09/2024 |
4 | Trevi Therapeutics, Inc. Given Average Rating of Buy by Analysts - MarketBeat | 09/24/2024 |
5 | Acquisition by James Cassella of 400000 shares of Trevi Therapeutics at 3.34 subject to Rule 16b-3 | 09/30/2024 |
6 | Trevi Therapeutics Provides Update on Haduvios Clinical Development Program | 10/03/2024 |
7 | Trevi Therapeutics Inc Q2 2024 Earnings Call Highlights Navigating Financial Challenges ... | 10/09/2024 |
8 | Trevi Therapeutics Given Buy Rating at HC Wainwright | 10/22/2024 |
9 | Trevi Therapeutics EPS of -0.13 misses by 0.02 | 11/06/2024 |
10 | Trevi Therapeutics Inc Q3 2024 Earnings Call Highlights Navigating Increased Losses and ... | 11/07/2024 |
11 | Trevi Therapeutics, Inc. Receives 7.43 Average PT from Brokerages - MarketBeat | 11/13/2024 |
12 | Landscape Capital Management L.L.C. Sells 180,717 Shares of Trevi Therapeutics, Inc. | 11/22/2024 |
About Trevi Therapeutics Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Trevi or other stocks. Alpha measures the amount that position in Trevi Therapeutics has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Payables Turnover | 0.068 | 0.0714 | Days Of Inventory On Hand | 8.0K | 7.6K |
Trevi Therapeutics Upcoming Company Events
As portrayed in its financial statements, the presentation of Trevi Therapeutics' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Trevi Therapeutics' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Trevi Therapeutics' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Trevi Therapeutics. Please utilize our Beneish M Score to check the likelihood of Trevi Therapeutics' management manipulating its earnings.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Trevi Therapeutics
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Trevi Therapeutics Backtesting, Trevi Therapeutics Valuation, Trevi Therapeutics Correlation, Trevi Therapeutics Hype Analysis, Trevi Therapeutics Volatility, Trevi Therapeutics History and analyze Trevi Therapeutics Performance. For more detail on how to invest in Trevi Stock please use our How to Invest in Trevi Therapeutics guide.You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Trevi Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.